Skip to main content
Epigenomics AG logo

Epigenomics AG — Investor Relations & Filings

Ticker · ECX ISIN · DE000A37FT41 LEI · 549300X1C4U862NDLN97 F Financial and insurance activities
Open in API
Filings indexed 90 across all filing types
Latest filing 2023-04-12 Report Publication Anno…
Country DE Germany
Listing F ECX

About Epigenomics AG

https://www.epigenomics.com/

Epigenomics AG operates as a holding company dedicated to managing its assets and investments. The company's primary investment focus is on the field of molecular diagnostics, particularly in companies developing minimally invasive, blood-based tests for the early detection of cancer. This strategy leverages the company's historical expertise in the development of in vitro diagnostic products based on DNA methylation biomarkers.

Recent filings

Filing Released Lang Actions
Hinweis auf Jahresfinanzbericht vom 01.01.2022 bis zum 31.12.2022
Report Publication Announcement Classification · 99% confidence The document is very short (781 characters) and its primary function is to announce where and when a financial report can be accessed. Key phrases include "Hinweis auf Jahresfinanzbericht" (Notice of Annual Financial Report) and providing a link and date for the report's availability online ("Im Internet unter: ...", "Im Internet am: 28.04.2023"). This structure perfectly matches the definition of a Report Publication Announcement (RPA), which is used when the document itself is merely an announcement, not the full report (Rule 2). Although it mentions an 'Annual Financial Report' (Jahresfinanzbericht), the document's content is the notice, not the report itself.
2023-04-12 German
Q3 statement / Q3 financial report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM STATEMENT 9M' and covers the period from January 1 to September 30, 2022. It contains comprehensive financial statements, including the Consolidated Statement of Profit or Loss, Consolidated Balance Sheet, Consolidated Statement of Cash Flows, and Consolidated Statement of Changes in Equity, along with detailed management analysis of the financial results. This meets the criteria for an Interim/Quarterly Report (IR). 9M 2022
2022-11-09 English
Half-yearly financial report 2022
Interim / Quarterly Report Classification · 100% confidence The document is a '6-Month Report' for Epigenomics AG covering the period from January 1 to June 30, 2022. It contains detailed interim consolidated financial statements, an interim group management report, and notes to the financial statements. This fits the definition of an Interim/Quarterly Report (IR) as it provides comprehensive financial data for a period shorter than a full fiscal year. H1 2022
2022-08-10 English
Hinweis auf Halbjahresfinanzbericht vom 01.01.2022 bis zum 30.06.2022
Report Publication Announcement Classification · 98% confidence The document text is very short (791 characters) and explicitly functions as a notice. Key phrases include 'Hinweis auf Halbjahresfinanzbericht' (Notice of Half-Year Financial Report) and details about where the report can be found online ('Im Internet unter:'). This structure—announcing the availability of a report rather than containing the full report content—fits the definition of a Report Publication Announcement (RPA). The report being announced is a 'Halbjahresfinanzbericht' (Half-Year Financial Report), which corresponds to an Interim Report (IR), but since this document is only the *notice* of publication, RPA is the correct classification based on Rule 2.
2022-08-02 German
Q1 statement / Q1 financial report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM STATEMENT Q1' for the period 'JANUARY 1–MARCH 31 2022'. It contains comprehensive financial statements, including the Consolidated Statement of Comprehensive Income, Consolidated Balance Sheet, Consolidated Statement of Cash Flows, and Consolidated Statement of Changes in Equity, along with detailed management analysis of the financial results. It is not an announcement of a report, but the report itself, fitting the definition of an Interim/Quarterly Report. Q1 2022
2022-05-11 English
Jahres- und Konzernabschluss zum Geschäftsjahr vom 01.01.2021 bis zum 31.12.2021
Audit Report / Information Classification · 98% confidence The document text contains detailed financial statements, specifically a 'BILANZ' (Balance Sheet) and 'Gewinn- und Verlustrechnung' (Profit and Loss Statement) for Epigenomics AG as of December 31, 2021, prepared according to German GAAP ('HGB'). It also includes the 'ANHANG' (Notes to the Financial Statements). The presence of full balance sheets, P&L statements, and extensive notes, covering an entire fiscal year, strongly indicates this is a comprehensive annual financial report. While the document is in German, the structure aligns perfectly with the content expected in an Annual Report (10-K equivalent for German reporting standards, though 10-K is the specific SEC code requested). Since it is the full set of annual accounts, it is classified as an Annual Report (10-K). It is not a short announcement (RPA/RNS) because the document length is substantial (262,850 chars) and contains the actual financial data, not just a reference to it. FY 2021
2022-04-11 German

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.